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A close connection: Alzheimer’s disease and type 2 diabetes 
ABSTRACT 
In the recent years a growing body of evidence 
links insulin resistance and insulin action to 
neurodegenerative diseases, especially Alzheimer’s 
disease (AD). The importance of insulin in ageing 
as well as its role in cognition and other aspects of 
normal brain functions are well established. The 
hippocampus and cerebral cortex-distributed insulin 
and insulin receptor (IR) have been shown to be 
involved in brain cognitive functions. Conversely, 
deterioration of IR signaling is involved in aging-
related brain degeneration such as in AD and 
cognitive impairment in type 2 diabetes patients. 
Insulin administration, while maintaining 
euglycemia, improves memory in both healthy 
adults and Alzheimer’s disease patients. In the 
present review, some common links between AD 
and type 2 diabetes are presented. Furthermore, 
several biochemical aspects existing in both 
pathologies are highlighted. 
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INTRODUCTION  
Alzheimer’s disease (AD) is the most common 
form of dementia in the elderly and covers more 
 
than 50% of all cases of dementia worldwide [1]. 
It is a neurodegenerative cognitive disorder with 
the typical features characterized by the impairment 
of memory, language, attention, executive 
functioning, apraxia, agnosia, and aphasia. 
Cognitive and also behavioral symptoms cause a 
reduction of functional activities compared to a 
previous level of functioning. At cellular level, 
AD is characterized by neuronal cell loss and 
increasing accumulation of neurofibrillary tangles 
(NFT) in neurons and amyloid fibers, due to the 
ordered aggregation of amyloid-beta peptide, in 
neuritic plaques and in the walls of blood vessels 
[2]. These structures progressively accumulate in 
the brain starting from the hippocampus and then 
spreading to the cerebral cortex where neurons are 
lost causing memory, language and in general 
cognitive impairment [3]. Amyloid beta-peptides 
of varying lengths (39-43 residues) are produced 
by cleavage of a large transmembrane protein, the 
amyloid beta-protein precursor (APP) [4]. The 42 
residue beta-peptide (Αβ-42) is the predominant 
form found in plaques and, under physiological 
conditions, the ratio between Αβ-42 and Αβ-40 is 
about 1:10 [5]. Αβ-42 has a neurotoxicity greater 
than Αβ-40 and its aggregation kinetics is faster 
than other beta-peptides [6]. A recent and now 
convincing belief is that small diffusible oligomers 
of Αβ-42, called ADDLs, are the determining 
pathogenic species causing synaptic dysfunction 
and eventually neuronal degeneration [7, 8]. 
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BMI > 30 kg/m [26]. In the last forty years the rate 
of obesity in the US has increased and nowadays 
66% of adults have a BMI > 25 kg/m2 and half of 
those have a BMI > 30 kg/m [27]. 
Another link between obesity, inflammation, insulin 
signaling and dementia is the amyloid precursor 
protein (APP) [28]. APP is considered an adipokyne, 
produced and processed in Aβ40-42 by adipose 
tissue. This fragment is expressed in fat tissues 
and overexpressed in abdominal adipocytes of 
obese patients [28]. 
Recent data support an increased susceptibility to 
AD in patients with MetS [29], although from the 
age of 85 and older the association between MetS 
and accelerated cognitive decline vanished [30]. 
On the other hand, some American scientists 
hypothesize that AD is a third form of diabetes 
[31]. This hypothesis was formulated in 2005 
when they analyzed 45 AD patients post-mortem, 
showing lower levels of insulin in the brain. In 
particular, the authors analyzed the frontal cortex 
of AD individuals, calculating the concentration 
of insulin, insulin-like growth factor 1 and insulin 
receptor. Data showed that later stages of disease 
were associated with decrease of these parameters 
up to 80% compared to healthy brain [31]. 
According to the latter association, some authors 
proposed the concept of “metabolic cognitive 
syndrome” when describing co-occurrence of AD 
and MetS. Indeed, dementia and MetS present 
some overlap both in predisposition factors and in 
altered signaling cascade. Environmental elements 
like diet, lifestyle, smoke and socio-economic 
status give a critical contribute to these disorders. 
Altered insulin signaling pathway has a key role 
in their pathogenesis. In particular insulin resistance 
might be the first step towards both disorders, 
constituting a bridge between AD and MetS [32]. 
It was previously thought that insulin did not play 
any significant regulatory role in the brain. 
However, many studies have demonstrated that 
insulin not only controls glucose and lipid 
metabolism in the brain, but also regulates neural 
development and neuronal activities and plays an 
important role in learning and memory [33, 34]. 
Furthermore, insulin has a crucial role in the 
neuroplasticity, that is the ability of the CNS to 
react to the environment. Both insulin and insulin 
receptor (IR) are found in the brain, and IR is 
highly expressed in brain neurons [35, 36]. 
Familial AD is a rare form of dementia and is 
caused by autosomal dominant mutations in one 
or more of the genes encoding the APP, presenilin 
1 or presenilin 2 (the latter two proteins form the 
catalytic core of γ-secretase) [9]. By contrast, late-
onset AD might be caused by environmental 
and/or lifestyle factors [10]. Interestingly, late-
onset AD is characterized not only by the 
neuropathological markers mentioned above, but 
also by vascular lesions, and hyperglycemia, 
hyperinsulinemia, insulin resistance, glucose 
intolerance, adiposity, atherosclerosis and 
hypertension [11]. Numerous studies report that 
patients with diabetes have an increased risk of 
developing AD if compared with healthy 
individuals [12-14] and some studies revealed that 
80% of patients with AD exhibited impairments 
either in glucose tolerance or diabetes [15]. In 
particular, similarities between type 2 diabetes 
(T2D) and AD include age-related processes, 
degeneration, high cholesterol levels, peripheral 
and CNS insulin resistance, dysfunctional insulin 
receptor (IR) and IR-mediated signaling pathways, 
decreased glucose transport and metabolism, 
despite the higher non-metabolized glucose levels 
in cerebral blood [16-18]. The unbalance between 
low and high glucose levels in T2D patients may 
be responsible for brain vascular damage and 
neurodegeneration thus facilitating the AD onset. 
Most recently, metabolic syndrome (MetS), which 
represents a cluster of metabolic factors such as 
insulin resistance, abdominal obesity, glucose 
intolerance, hypertension, hyperinsulinemia and 
raised fasting plasma glucose has also been 
described in association with an increased risk of 
AD [19, 20]. Interestingly, strong evidences suggest 
that systemic inflammation and central adiposity 
contribute to and perpetuate MetS [21, 22]. All 
these alterations predispose individuals to type 2 
diabetes and cardiovascular disease [21-24]. 
Genetic background, age, sex, diet, physical 
activity, and habits in general all influence the 
prevalence of the MetS and its components. In the 
Mediterranean area, already 20 years ago, it was 
assessed that 70% of adults have at least one of 
the disorders characterizing MetS. However, in 
European population the rate of MetS is 7-30% [25]. 
Worldwide there are 1.1 billion overweight 
people with a body mass index (BMI) between 
25 kg/m2 and 30 kg/m2 and 312 million with a 
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metabolism is of pivotal significance for the 
maintenance of CNS structure and function [45], 
its regulation by insulin remains controversial. 
More recently, it has been suggested that cerebral 
glucose metabolism is controlled by neuronal 
insulin/IR signaling pathways [38, 46, 47]. Thus, 
brain can be regarded both as an insulin- and 
glucose-sensitive tissue [48]. 
Insulin resistance is a central feature of type 2 
diabetes and increasing evidence supports 
that insulin resistance is present in AD, 
contributing to neurodegeneration processes 
[49, 50]. Overexpression of Aβ in transgenic mice 
results in reduced glucose utilization [41], thus 
causing the typical effects of insulin resistance. 
Different mechanisms have been proposed to 
explain the insulin resistance in AD. Lee and 
coworkers [51] showed that in cell culture, Aβ 
expression inhibited both insulin-induced Akt 
phosphorylation and activity. Aβ oligomers, more 
than large structured aggregates, specifically 
interrupted the PDK-dependent activation of Akt. 
Aβ also blocked the association between PDK and 
Akt in cell-based and in vitro experiments. 
Furthermore, Aβ oligomers reduced both activation 
of insulin receptors and the levels of phospho-Akt 
[52] (Figure 1). In mature cultures of hippocampal 
neurons, ADDLs linked to dendrites cause a rapid 
and substantial loss of neuronal surface insulin 
receptors (IRs) [53]. Removal of dendritic IRs is 
associated with increased receptor immunoreactivity, 
indicating its redistribution in the cell body. The 
neuronal response to insulin, measured by evoked 
IR tyrosine autophosphorylation, is greatly 
inhibited by ADDLs [53, 54]. Moreover, decreased 
IR expression, its desensitization, and/or tyrosine 
kinase inactivity are reported in AD brain [31, 39]. 
Defects in IGF-I receptor and increase in the 
phospho-inactive form of IRS-1 and IRS-2 in AD 
have recently been found, further indicating 
resistance to insulin-like growth factor-1, IGF-1, 
signaling [55]. Insulin, IR, IGF-1 receptor 
(IGF-1R), insulin receptor substrate-1 (IRS-1) and 
insulin receptor substrate-2 (IRS-2) mRNA and 
protein levels decrease in age- and AD-related 
diseases [31, 55-58]. Interestingly, persistent and 
pathological hyperactivation of Akt-mTOR-S6K 
signaling pathways within AD neurons may 
increase IRS-1 phosphorylation at Ser312 or 616, 
Data discussed below are consistent with the view 
that diabetes-related dysfunction is exacerbated by 
aging and/or by the presence of neurotoxic agents, 
such as Aβ, suggesting that diabetes and aging are 
risk factors for the neurodegeneration induced by 
these peptides. An association between diabetes 
and AD has long been recognized. Here we 
presented evidence that the association between 
diabetes and AD signifies a common underlying 
pathology. 
 
Metabolism of glucose and insulin resistance   
in AD 
Glucose is, by far, the major brain energy substrate, 
and it maintains cerebral metabolism due to the 
combination of relatively high plasma glucose 
concentration and the presence of powerful 
transporters (GLUT1-5, 7 and 8), responsible for 
facilitated diffusion of glucose across the blood-
brain barrier (BBB), the plasma membrane of 
neurons and glial cells [37, 38]. Glucose uptake 
and metabolism are impaired in AD brain, and 
this impairment appears to be a cause, rather than 
a consequence, of neurodegeneration [39]. A 
reduction in the cerebral metabolic rate of glucose 
utilization is one of the most predominant 
abnormalities generally found in AD brain. PET 
with fluorodeoxyglucose (FDG) has been 
approved in the USA for diagnostic purposes and 
it is sensitive and specific in detecting AD in its 
early stages [40]. Impaired glucose uptake is 
found in transgenic mouse models of AD [41, 42]. 
During early stages of AD, glucose utilization 
deficit (50%) is greater than blood flow/oxygen 
deficits (20%), and only in the later stages of AD 
do the changes in these factors become similar 
[43]. This suggests that the glucose utilization 
deficit may be more important in the genesis of 
pathology than blood flow and oxygen utilization. 
Moreover, recently, it has been shown that the 
levels of the two major brain glucose transporters 
(GLUT1 and GLUT3), responsible for glucose 
uptake into neurons, are decreased in AD brain 
[44]. This decrease is correlated with the decrease 
in O-GlcNAcylation, hyperphosphorylation of tau 
protein, and density of NFT in human brain [44]. 
Taken together, these findings suggest a 
contribution of glucose metabolism in the early 
pathophysiology of AD. Although brain glucose 
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ii) impaired brain Aβ and insulin degradation in 
IDE knockout mice [67-69]; iii) increased IDE 
immunoreactivity around senile plaques and 
iv) enhanced IDE activity in IDE and APP double 
transgenic mice associated with a decrease in Aβ 
[70]. 
 
Metabolic-cognitive syndrome: Insulin and 
central nervous system (CNS) 
Insulin is known as a peripheral regulator of nutrient 
storage but it is also essential for the control of 
energy balance in the CNS. Neuronal insulin 
signaling pathway has an important function in 
mammals fat storage, and in C. elegans and 
Drosophila the cellular signaling systems 
mediating these effects bear remarkable homology 
to those described in mammals [71]. 
There are many evidences that demonstrate the 
insulin action in the control of neuronal function 
in cortical and hippocampal areas, involved in 
memory process and cognitive functioning [59, 72]. 
Insulin directly influences neurons by processes 
not linked to modulation of glucose uptake. 
Neurotransmitters release, neuronal-outgrowth, 
tubulin activity, neuronal survival and synaptic 
plasticity are all directly modulated by insulin 
[73-76]. Insulin signaling pathway modulates 
synaptic plasticity by: i) promoting the recruitment 
of GABA receptors (gamma-aminobutyric acid 
receptor) on post-synaptic membranes; ii) influencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
resulting in IRS-1/2 degradation, thus impairing 
IR-associated neurotrophic and metabolic brain 
functions [55]. Taken together, these findings 
confirm that AD can be considered an “insulin-
resistant brain state” or even a “type 3 diabetes”. 
Chronic peripheral hyperinsulinemia typical of 
type II diabetes is associated with insulin resistance 
in the brain, because initially high brain insulin 
levels tend to decrease, due to a downregulation 
of its supposed brain synthesis and/or transport 
[59]. The abnormalities in the insulin signal 
transduction cascade have an impact on APP 
trafficking causing an intracellular accumulation 
of Aβ. Furthermore, the hyperphosphorylation of 
tau protein and the consequent formation of 
neurofibrillary tangles (NFT) are enhanced by 
insulin signal transduction abnormalities and low 
levels of ATP. Thus, it is not surprising that insulin 
resistance increases Aβ levels and inhibits insulin 
signaling in the AD transgenic mice Tg2576 [60]. 
Another potential mechanism could be the 
interference of insulin with extracellular proteolytic 
Aβ degradation by the insulin-degrading enzyme 
(IDE), a metalloprotease involved in the insulin 
and IGF-1 metabolism. Under this perspective, 
insulin resistance may competitively inhibit IDE, 
thus impairing Aβ degradation, increasing its 
neurotoxicity and promoting AD [47, 59, 61-66]. 
This suggestion is supported by: i) a decrease in IDE 
activity and mRNA and protein levels in AD brain; 
Figure 1. Insulin, by binding to its own receptor (IR), activates the signaling pathway via Akt 
phosphorylation. The presence of Aβ oligomers inhibit IR activation and the correlated signaling. 
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receptor, thus its inefficient degradation might 
play a key role in AD brain insulin resistance 
[54]. 
 
Mitochondrial dysfunction and oxidative stress: 
A further link between diabetes and AD  
Diabetes and AD are associated with deficits in 
mitochondrial activity, metabolic dysfunction and 
oxidative stress [79-83]. Increasing data support 
the idea that mitochondrial function declines with 
aging and in age-related diseases, such as diabetes 
and AD [80, 84]. Mitochondria are the subcellular 
organelles, essential for generating the energy that 
fuels normal cellular function and, at the same 
time, they monitor cellular health in order to make 
a rapid decision (if necessary) to initiate a 
programmed cell death. Accumulating evidence 
suggests that mitochondrial dysfunction is intimately 
associated with AD pathophysiology. Aβ interacts 
with Aβ-binding dehydrogenase (ABAD) in 
mitochondria of AD patients and in transgenic 
mouse brains, suggesting that ABAD is a direct 
molecular link between Aβ and mitochondrion 
[85]. Moreover, it has been reported that ABAD 
enhances Aβ-induced cell stress via mitochondrial 
dysfunction [86]. It has, also, demonstrated that 
the Aβ is imported into mitochondria via the 
translocase of the outer membrane (TOM) 
machinery, independently of the mitochondrial 
membrane potential [87]. In 2004, Swerdlow and 
Khan [88] proposed the “mitochondrial cascade 
hypothesis”. It postulates that mitochondrial 
dysfunction represents a primary pathology in 
sporadic/late-onset AD. The most consistent 
defects in mitochondria in AD, are deficiencies 
in several key enzymes responsible for 
oxidative metabolism including α-ketoglutarate 
dehydrogenase complex (KGDHC) and pyruvate 
dehydrogenase complex (PDHC), two enzymes 
involved in the rate-limiting step of tricarboxylic 
acid cycle, and cytochrome c oxidase (COX), the 
terminal enzyme in the mitochondrial respiratory 
chain [89-95]. These functional abnormalities in 
mitochondria favor the production of ROS and, 
consequently, electron transport, ATP production, 
and mitochondrial membrane potential all become 
impaired. In conclusions, mitochondrion can be 
considered both the source and the target of 
oxidative stress induced by Aβ. Moreover, increased 
production of reactive oxygen and nitrogen 
 
NMDA receptor (N-methyl D-aspartate receptor) 
conductance (neuronal Ca2+ influx) and 
iii) regulating AMPA receptor (a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor) cycling. 
The Metabolic-Cognitive Syndrome (MCS) was 
elaborated on 2010 by Frisardi and his colleagues. 
It is based on the co-existence, in patients, of 
MetS and cognitive impairment of degenerative 
or vascular origin [32]. Insulin resistance can 
be manifested in peripheral tissues or directly in 
the brain as insulin-resistant brain state, thus 
contributing to cognitive impairment and 
neurodegeneration for the reason described above 
[32]. 
Many molecules participate in the regulation of 
insulin signaling pathway, therefore an alteration 
in the function or expression of some of these 
proteins causes a reduction in glucose uptake. 
Consequently glucose is accumulated in the blood 
determining hyperglycemia and hyperinsulinemia. 
Hyperglycemia induces an increase of peripheral 
utilization of insulin which results in a reduction 
of insulin disposable for the brain. As insulin is 
essential for memory, learning, neuronal survivor 
and longevity processes, the alteration of 
its concentration might cause important 
consequences on tau and Aβ processing [59, 72]. 
For example, an impairment of insulin signaling 
pathway causes a reduction of the activity of 
phosphatidylinositol 3-kinase (PI3K) and 
consequently a reduction in AKT/PKB pathway. 
This leads to an increase of glycogen synthase 
kinase 3 α/β (GSK-3 a/b) activity that 
phosphorylates tau protein and causes 
intraneuronal Aβ accumulation [31]. Moreover, 
glucose metabolism plays a role in the protein 
post-translational modification involving the 
hexosamine biosynthetic pathway, which leads to 
the generation of O-N-acetylglycosamine (O-Glc-
NAc). If insulin resistance is established, 
intraneuronal glucose metabolism is impaired. 
Consequently, the amount of O-Glc-NAcylation is 
reduced. This post-translational modification 
competes with phosporylation process, thus more 
phosphate groups are added, with an increase of 
the amount of phosphorylated tau protein [77]. 
Insulin is also involved in the metabolism of APP 
[78] and the latter, in turn, competes with insulin 
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of type 1 diabetes, possess a lower content of 
coenzyme Q9 (CoQ9) indicating a deficit in 
antioxidant defenses in diabetic animals and, 
consequently, an increased probability of oxidative 
stress occurrence [106]. In addition, the decrement 
in oxidative phosphorylation (OXPHOS) efficiency 
is related to a loss in the control of glucose 
homeostasis as evidenced by the increase in tissue 
and blood lactate levels, as well as by the change 
in glucose tolerance. Cytoplasmic hybridor 
“cybrid” (eukaryotic cell produced by the fusion 
of a whole cell with a cytoplasm) cells 
constructed from individuals with maternally 
inherited diabetes exhibited lactic acidosis, poor 
respiration and marked defects in mitochondrial 
morphology and respiratory chain complex I and 
IV activities [107]. Data show the existence of an 
age-related impairment of the respiratory chain 
and an uncoupling of OXPHOS in brain 
mitochondria isolated from Goto-Kakizaki (GK) 
rats, a model of type 2 diabetes. Furthermore, 
aging exacerbates the decrease in the energetic 
levels promoted by diabetes [108]. The 
maintenance of OXPHOS capacity is extremely 
important in the brain since about 90% of the ATP 
required for the normal functioning of neurons is 
provided by mitochondria. Diabetes decreases the 
capacity of mitochondria to accumulate Ca2+, a 
favorable intracellular environment for MPT 
opening [108, 109].  
species, coinciding with a depletion of antioxidant 
defenses is observed in neuronal systems after Aβ 
treatment [96] and the assumption of natural 
antioxidants, such as vitamins C and E, promises 
to be a powerful preventive treatment against AD 
occurrence [97-100]. Recently, it has been shown 
[101] that AD patients present a significantly 
lower expression of 70% of the nuclear genes 
encoding subunits of the mitochondrial electron 
transport chain in posterior cingulate cortex, 65% 
of those in the middle temporal gyrus, 61% of 
those in hippocampal CA1, 23% of those in 
entorhinal cortex, 16% of those in visual cortex, 
and 5% of those in the superior frontal gyrus, if 
compared with healthy individuals. Mitochondria 
are also important cytoplasmic calcium ion 
buffers since they avoid the increase of Ca2+ 
above a critical value termed “set-point”. In 
oxidative stress conditions, a sustained increase in 
intracellular Ca2+ concentration occurs (Figure 2) 
[102] and the cytosolic calcium levels play a role 
in the modulation of several intracellular signaling 
pathways, including protein kinase C-α and 
calmodulin-dependent signaling [103] which have 
also been implicated in apoptotic processes. It has 
been observed that Aβ exacerbates Ca2+-induced 
opening of mitochondrial permeability transition 
pores (MPT) without inducing the permeability 
per se [104, 105]. Brain mitochondria isolated 
from streptozotocin (STZ) diabetic rats, a model 
 
 
Figure 2. A vicious circle triggered by insulin resistance. Insulin resistance induces mitochondrial 
dysfunction generating ROS production that, in turn, increases Aβ oligomers formation, thus stimulating 
AD progression. The effects of mitochondrial dysfunction are the inhibition of the electron transport 
chain and the increase of Ca++ release. 
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The formation and accumulation of AGEs occurs 
during normal aging; however, these processes are 
exacerbated in patients with diabetes and the 
binding of AGE to its receptor (receptor for AGEs 
or RAGE) induces a series of biological processes 
that cause further diabetic complications [113]. 
AGE immunoreactivity is present in both Aβ 
plaques and NFTs in patients with AD. Furthermore, 
hippocampal neurons from patients with this 
neurodegenerative disease contain Aβ-positive, 
AGE-positive and RAGE positive granules. [114]. 
Whether the modifications of Aβ and tau by 
AGEs are a primary or secondary event in AD is 
a controversial topic. Nevertheless, AGEs are 
widely accepted to be active participants in the 
progression of AD, since AGE-induced glycation 
of Abeta and tau protein has been shown to cause 
the Abeta aggregation and the formation of NFTs, 
respectively [115]. Moreover, diabetic mice with 
cognitive impairments exhibit increased RAGE 
expression in neurons and glia compared with 
wild-type control mice [116], and in one clinical 
study, AGE immunostaining was increased in 
postmortem brain slices from patients with AD 
and diabetes compared with non-diabetic patients 
with AD [117]. 
The question of whether AGEs are the cause or 
consequence of the pathology is not clear, 
although there is likely a primary role of oxidative 
stress in both the pathologies. However, it should 
be pointed out that glycoxidation and oxidative 
stress are mutually dependent and reinforce each 
other. Thus, while the sources of oxidative stress 
may widely differ in diabetes and AD, and while a 
number of AGEs accumulate in both conditions, 
other AGEs found in diabetes have yet to be 
characterized in AD. 
 
Inflammation in Alzheimer’s disease and 
diabetes 
Inflammation is a teleonomic response to eliminate 
the initial cause of cell injury as well as the 
necrotic cells and tissues resulting from the original 
insult. If tissue health is not restored in response 
to stable low grade irritation, inflammation becomes 
a chronic condition that continuously erodes the 
surrounding tissues. In fact, in chronic inflammation 
immune responses, tissue injury and healing 
proceed simultaneously. The lateral damage caused 
 
Advanced glycation end products (AGE) 
Abnormal glucose metabolism and oxidative 
stress contribute to the formation of advanced 
glycation end products (AGE). These molecular 
species are formed through the Maillard reaction 
or “non-enzymatic browning”, a complex series of 
reactions between reducing carbohydrates with 
lysine side chains and N-terminal amino groups of 
proteins. The first step of the process leads to the 
rather labile Schiff bases which as a rule rearrange 
to the more stable Amadori products. These are 
slowly degraded, in complex reaction pathways 
via dicarbonyl intermediates, to a plethora of 
compounds [110] designated summarily as 
“advanced glycation end products” (AGEs). The 
reaction sequence proceeds both in vitro and 
in vivo. In long-lived tissue proteins, these 
chemical modifications accumulate with age and 
may contribute to pathophysiologies associated 
with aging and long-term complications of 
diabetes and atherosclerosis [111]. 
Practically, AGEs comprise a heterogeneous group 
of molecules formed by irreversible, non-enzymatic 
reactions between sugars and the free amino 
groups of proteins, lipids and nucleic acids. 
Auto-oxidation of glucose leads to the formation 
of oxygen radicals, which are intermediates in the 
AGE pathway and the predominant source of 
endogenous AGEs. AGEs may exist as protein 
cross-links or as modification of the side chains of 
a single protein, and significantly alter the protein 
conformations leading to protein inactivation. 
Numerous AGEs have been isolated and 
characterized after cleavage from the protein 
backbones, by spectroscopic analysis. AGEs 
involving protein cross-links include pentosidine 
(a dimer of arginine and lysine), methylglyoxal-
lysine dimer (MOLD, a dimer of two lysine residues), 
methylglyoxal-derived imidazolium cross-link 
(MODIC) and glyoxal-derived imidazolium cross-
link (GODIC, dimers of arginine and lysine 
residues). Examples of AGEs resulting from the 
single protein modification are pyrraline and Nε -
(carboxymethyl)lysine (CML), the lysine-residue 
modified products, and arg-pyrimidine, an 
arginine-residue modified protein. Although many 
other AGEs, including the hydroimidazolone adduct 
MG-H1, have been characterized in diabetes, some 
of them have common occurrence in AD [112]. 
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systemic inflammation. In fact a strong local 
inflammatory stimulus such as a previous head 
trauma is a risk factor for AD and several 
epidemiological studies clearly show that blood 
elevations of acute phase proteins, markers of 
systemic inflammatory stimuli, may be risk 
factors for cognitive decline and dementia. 
Furthermore, in experimental animals, chronic 
systemic inflammatory response induced by 
lipopolysaccharide administration also induces 
glial activation [121]. 
The basic function of astrocytes is to protect 
neurons. In the early phase of AD there is an 
astrogliosis that represent a response to the 
accumulation of the amyloid beta in the brain 
parenchyma and in the cerebral microvasculature 
[122].  
Migration of astrocytes to amyloid beta plaques is 
promoted by the chemochines CCL2 and CCL3 
released by activated microglial cells that 
surround the plaques [123].  
There is the evidence that indicates an 
involvement of the immune system, other than 
neuroinflammatory processes in CNS, accompanied 
by changes or defects in immune responses in the 
blood of AD subjects [124]. 
The molecular and cellular components that 
mediate the communication between peripheral 
inflammation and the brain, have been studied 
in experimental models, and major routes 
of communication are known. All of them lead to 
the synthesis of cytokines and inflammatory 
mediators in the brain parenchyma, phenomena 
typically associated with tissue injury [125]. 
In recent years, much has been learned about the 
intracellular signaling pathways activated by 
inflammatory and stress responses and how these 
pathways intersect with and inhibit insulin signaling. 
Insulin affects cells through binding to its receptor 
on the surface of insulin-responsive cells. The 
stimulated insulin receptor phosphorylates itself 
and several substrates, including members of 
the insulin receptor substrate (IRS) family, thus 
initiating downstream signaling events [126, 127]. 
The inhibition of signaling downstream of the 
insulin receptor is a primary mechanism through 
which inflammatory signaling leads to insulin 
 
by this type of inflammation usually accumulates 
slowly, sometimes asymptomatically for years 
and can lead to severe tissue deterioration. A 
characteristic feature of chronic inflamed tissues 
is the presence of an increased number of 
monocytes, as well as monocyte derived tissue 
macrophages, i.e. microglia cells in the central 
nervous system [118]. 
Inflammation clearly occurs in pathologically 
vulnerable regions of the AD brain, with increased 
expression of acute phase proteins and pro-
inflammatory cytokines which are hardly evident 
in normal brain [119]. 
Since amyloid fibrils represents a chronic stimulus, 
the innate immune systems clearly makes an 
initial attempt to clear these potentially toxic 
products. The hypothesis is that the intractable 
nature of the plaques and tangles stimulates a 
chronic inflammatory reaction to clear this debris. 
Activated cells strongly produce inflammatory 
mediators as pro-inflammatory cytokines 
interleukin-1β (IL-1β), IL-6, and TNF-α as well as 
the chemokine IL-8,macrophage inflammatory 
protein-1α, and monocyte chemo-attractant protein-1, 
prostaglandins, leukotrienes, thromboxanes, 
coagulation factors, ROS and other radical 
molecules, nitric oxide, complement factors, 
proteases, and protease inhibitors and pentraxins, 
such as C-reactive protein and serum amyloid 
Pcomponent [120]. 
The genes involved in the inflammation process 
are numerous and the role of an individual genetic 
background might show a predisposition to 
inflammation and its healthy or chronic 
resolution. Research in AD patients have found 
some functional polymorphisms, mostly single 
nucleotide polymorphisms (SNPs), in the 
promoter region or other untranslated regions of 
genes encoding inflammatory mediators or their 
enzymes. Actually, Primary responses are mediated 
by pathogen recognition receptors such as Toll-
like receptor (TLR), pro-inflammatory cytokines 
such as TNF-α, IL-1 and IL-6, anti-inflammatory 
cytokines such as IL-10 and eicosanoids [3]. 
Aggregated amyloid fibrils and inflammatory 
mediators secreted by microglial and astrocytic 
cells equally contribute to neuronal dystrophy. 
The microglia activation can be due to local or 
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